Investigation of epidermal growth factor containing liposome formulation effects on burn wound healing

Journal of Biomedical Materials Research - Part A

Volumn 85, Issue 1, 2008, Pages 271-283

  Alemdaroǧlu, Ceren ^a   Degim, Zelihagül ^a   Celebi, Nevin ^a   Şengezer, Mustafa ^b   Alömeroglu, Melih ^b   Nacar, Ahmet ^c  

^a GAZI UNIVERSITY   (Turkey)

^b GULHANE SCHOOL OF MEDICINE   (Turkey)

^c GAZI UNIVERSITY FACULTY OF MEDICINE   (Turkey)

Author keywords

Burn; Epidermal growth factor (EGF); Liposome; Wound healing

Indexed keywords

BIOPSY; FILM PREPARATION; LIPOSOMES; MEDICAL PROBLEMS; RATS; TRANSMISSION ELECTRON MICROSCOPY;

BURN WOUND HEALING; EPIDERMAL GROWTH FACTORS; LIPOSOME FORMULATIONS; VISION SCREENING ANALYSIS PROGRAMS;

CELL GROWTH;

BROXURIDINE; EPIDERMAL GROWTH FACTOR; LIPOSOME; SILVERDINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BURN; CONTROL GROUP; CONTROLLED STUDY; DRUG EFFICACY; DRUG FORMULATION; EPIDERMIS; FIBROBLAST; HISTOLOGY; HUMAN; IMAGE ANALYSIS; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; NONHUMAN; RAT; SKIN BIOPSY; SPECTROFLUOROMETRY; STAINING; STATISTICAL SIGNIFICANCE; TRANSMISSION ELECTRON MICROSCOPY; TRICHROME STAIN; VISION SCREENING ANALYSIS PROGRAM; WOUND HEALING;

EID: 40449124452     PISSN: 15493296     EISSN: 15524965     Source Type: Journal    
DOI: 10.1002/jbm.a.31588     Document Type: Article

References (36)

1. 1 Schultz G, Rotatori DS, Clark W. EGF and TGF‐α in wound healing and repair. J Cell Biochem 1991 ; 45: 346–352.
2. 2 Fu X, Shen Z, Chen Y, Xie J, Guo Z, Zhang M, Sheng Z. Randomised placebo‐controlled trial of use of topical recombinant bovine basic fibroblast growth factor for second‐degree burns. Lancet 1998 ; 352: 1661–1664.
3. 3 Çelebi N, Erden N, Gönül B, Koz M. Effects of epidermal growth factor dosage forms on dermal wound strength in mice. J Pharm Pharmacol 1993 ; 46: 386–387.
4. 4 Gonul B, Akbulut KG, Ozer C, Yetkin G, Celebi N. The role of transforming growth factor alpha formulation on aspirin‐induced ulcer healing and oxidant stress in the gastric mucosa. Surgery Today 2004 ; 34: 1035–1040.
5. 5 Brown GL, Curtsinger LJ, White M, Mitchell RO, Pietsch J, Nordquist R, Fraunhofer A, Schultz GS. Acceleration of tensile strength of incisions treated with EGF and TGF‐β. Ann Surg 1988 ; 208: 788–794.
6. 6 Kiyohara Y, Nishiguchi K, Komada F, Iwakawa S, Hirai M, Okumura K. Cytoprotective effects of epidermal growth factor (egf) ointment containing nafamostat, a protease inhibitor, on tissue damage at burn sites in rats. Biol Pharm Bull 1993 ; 16: 1146–1149.
7. 7 Schultz GS, White M, Mitchell R, Brown G, Lynch J, Twardzik DR, Todaro GJ. Epithelial wound healing enhanced by transforming growth factor‐α and vaccinia growth factor. Science 1987 ; 235: 350–352.
8. 8 Crommelin DJA, Schreler H. Liposomes. In: Kreuter J, editor. Colloidal Drug Delivery Systems. USA: Marcel Dekker ; 1994. p 73–157.
9. 9 Yerushalmi N, Margalit R. Bioadhesive, collagen‐modified liposomes: Molecular and cellular level studies on the kinetics of drug release and on binding to cell monolayers. Biochim Biophys Acta 1994 ; 1189: 13–20.
10. 10 Yerushalmi N, Arad A, Margalit R. Molecular and cellular studies of hyaluronic acid‐modified liposomes as bioadhesive carriers for topical drug delivery in wound healing. Archiv Biochem Biophys 1994 ; 313: 267–273.
11. 11 Li H, Song JH, Park SJ, Han K. Polyethylene glycol‐coated liposomes for oral delivery of recombinant human epidermal growth factor. Int J Pharm 2003 ; 258: 11–19.
12. 12 Allen TM. Liposomes. Opportunities in drug delivery. Drugs 1997 ; 54 ( Suppl 4): 8–14.
13. 13 Gerasimov OV, Boomer JA, Qualls MM, Thompson DH. Cytosolic drug delivery using pH‐ and light sensitive liposomes. Adv Drug Deliv Rev 1999 ; 38: 317–338.
14. 14 Celebi N, Türkyilmaz A, Gönül B, Özogul C. Effects of epidermal growth factor microemulsion formulation on the healing of stress‐induced gastric ulcers in rats. J Control Release 2002 ; 83: 97–210.
15. 15 Dogan AK, Gumusderelioglu M, Aksoz E. Controlled release of EGF and b‐FGF from dextran hydrogels in vitro and in vivo. J Bıomed Mater Res Part B: Appl Bıomater 2005 ; 74: 504–510.
16. 16 Vorauer‐Uhl K, Furnschlief E, Wagner A, Ferko B, Katinger H. Topically applied liposome encapsulated superoxide dismutase reduces postburn wound site and edema formation. Eur J Pharm Sci 2001 ; 14: 63–67.
17. 17 Sugihara H, Hattori T, Fukuda M. Immunohistochemical detection of bromodeoxyuridine in formalin fixed tissues. Histochemistry 1986 ; 85: 193–195.
18. 18 Montero‐Montoya R, Serrano L, Ostrosky‐Wegman P. In vitro induction of micronuclei in lymphocytes: The use of bromodeoxyuridine as a cell proliferation marker. Mutat Res 1997 ; 391: 135–141.
19. 19 Alemdaroğlu C, Değim Z, Çelebi N, Zor F, Öztürk S, Erdoğan D. An investigation on burn wound healing in rats with chitosan gel formulation containing epidermal growth factor. Burns 2006 ; 32: 319–327.
20. 20 Pearson AS, Wolford W. Management of skin trauma. Prim Care 2000 ; 27: 475–492.
21. 21 Bangham AD, Standish MM, Watkins JC. Diffusion of univalent ions across the lamellae of swollen phospholipids. J Mol Biol 1965 ; 13: 238–252.
22. 22 Al‐Angary AA, Bayomi MA, Khidr SH, Al‐Meshal MA, Al‐Dardiri M. Characterization, stability and in vivo targeting of liposomal formulations containing cyclosporin. Int J Pharm 1995 ; 114: 221–225.
23. 23 Lichtenstein A, Margalit R. Liposome‐encapsulated silver sulfadiazine (SSD) for the topical treatment of infected burns: Thermodynamics of drug encapsulation and kinetics of drug release. J Inorg Biochem 1995 ; 60: 187–198.
24. 24 Lasic DD. Novel applications of liposomes. Tibtech 1998 ; 16: 307–321.
25. 25 Shabbits JA, Chiu GNC, Mayer LD. Development of an in vitro drug release assay that accurately predicts in vivo drug retention for liposome‐based delivery systems. J Control Release 2002 ; 84: 161–170.
26. 26 Montelione GT, Wuthrich K, Burgess AW, Nice EC, Wagner G, Gibson KD, Scheraga HA. Solution structure of murine epidermal growth factor determined by NMR spectroscopy and refined by energy minimization with restraints. Biochemistry 1992 ; 31: 236–249.
27. 27 Kohda D, Go N, Hayashi K, Inagaki F. Tertiary structure of mouse epidermal growth factor determined by two‐dimensional 1H NMR. J Biochem 1988 ; 103: 741–743.
28. 28 Medved LV, Orthner CL, Lubon H, Lee TK, Drohan WN, Ingham KC. Thermal stability and domain–domain interactions in natural and recombinant protein C. Am Soc Biochem Mol Biol 1995 ; 270: 13652–13659.
29. 29 The Merck Index, 12th ed. Whitehouse Station, NJ, USA: Merck & Co., Inc. ; 1996. p 595–596.
30. 30 Maeda K, Kato Y, Sugiyama Y. pH‐dependent receptor/ligand dissociation as a determining factor for intracellular sorting of ligands for epidermal growth factor receptors in rat hepatocytes. J Control Release 2002 ; 82: 71–82.
31. 31 Quality of biotechnological products: Stability testing of biotechnological/biological products USP 26. In: 9th ed, The United States Pharmacopeia, Rockville, MD; 2003. p 2306–2309.
32. 32 Yang CH, Huang YB, Wu PC, Tsai YH. The evaluation of stability of recombinant human epidermal growth factor in burn‐injured pigs. Process Biochem 2005 ; 40: 1661–1665.
33. 33 Zhang XJ, Chinkes DL, Ramanujam VMS, Wolfe RR. Local injection of insulin‐zinc stimulates DNA synthesis in skin donor site wound. Wound Rep Reg 2007 ; 15: 258–265.
34. 34 Wenczak BA, Lynch JB, Nanney LB. Epidermal growth factor receptor distribution in burn wounds. J Clin Invest 1992 ; 90: 2392–2401.
35. 35 Ross MH, Kaye GI, Pawlina W. Connective Tissue in Histology: A Text and Atlas, 4th ed. Philadelphia, USA: Lippincott Williams and Wilkins ; 2003. Chapter 5. p 126–148.
36. 36 Degreef H, Michiels JL. 1% silver sulfadiazine cream as a treatment for infected leg ulcers. Curr Ther Res 1984 ; 36: 1190–1194.